Leerink Partnrs Has Bullish Forecast for KYMR Q2 Earnings

Kymera Therapeutics, Inc. (NASDAQ:KYMR) – Stock analysts at Leerink Partnrs raised their Q2 2025 earnings estimates for shares of Kymera Therapeutics in a research note issued on Monday, June 2nd. Leerink Partnrs analyst F. Khurshid now expects that the company will earn ($1.08) per share for the quarter, up from their prior estimate of ($1.18). The consensus estimate for Kymera Therapeutics’ current full-year earnings is ($2.79) per share. Leerink Partnrs also issued estimates for Kymera Therapeutics’ Q3 2025 earnings at ($1.12) EPS, Q4 2025 earnings at ($1.23) EPS, FY2025 earnings at ($4.25) EPS and FY2026 earnings at ($4.76) EPS.

Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Friday, May 9th. The company reported ($0.82) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.10. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The firm had revenue of $22.10 million during the quarter, compared to the consensus estimate of $11.38 million. During the same quarter in the prior year, the company earned ($0.69) EPS. The company’s revenue was up 114.6% on a year-over-year basis.

A number of other research firms have also recently issued reports on KYMR. Morgan Stanley upgraded Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $49.00 to $79.00 in a research note on Tuesday. Guggenheim reiterated a “buy” rating and issued a $52.00 target price on shares of Kymera Therapeutics in a research note on Monday, May 12th. Citigroup initiated coverage on Kymera Therapeutics in a research note on Thursday, March 13th. They issued a “buy” rating and a $52.00 target price on the stock. Stifel Nicolaus initiated coverage on Kymera Therapeutics in a research note on Tuesday, May 20th. They issued a “buy” rating and a $55.00 target price on the stock. Finally, Bank of America upgraded Kymera Therapeutics from a “neutral” rating to a “buy” rating and set a $51.00 target price on the stock in a research note on Monday. Two investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $59.35.

Kymera Therapeutics Trading Up 1.6%

KYMR stock opened at $44.26 on Thursday. Kymera Therapeutics has a twelve month low of $19.45 and a twelve month high of $53.27. The company has a market capitalization of $2.88 billion, a P/E ratio of -18.91 and a beta of 2.07. The firm has a 50 day simple moving average of $29.40 and a 200-day simple moving average of $35.71.

Institutional Investors Weigh In On Kymera Therapeutics

Large investors have recently added to or reduced their stakes in the business. Blue Trust Inc. raised its position in Kymera Therapeutics by 74.8% during the fourth quarter. Blue Trust Inc. now owns 631 shares of the company’s stock valued at $25,000 after purchasing an additional 270 shares in the last quarter. KBC Group NV grew its stake in shares of Kymera Therapeutics by 15.2% in the first quarter. KBC Group NV now owns 2,479 shares of the company’s stock worth $68,000 after purchasing an additional 328 shares during the last quarter. Summit Investment Advisors Inc. grew its stake in shares of Kymera Therapeutics by 9.0% in the fourth quarter. Summit Investment Advisors Inc. now owns 4,912 shares of the company’s stock worth $198,000 after purchasing an additional 406 shares during the last quarter. Comerica Bank boosted its position in Kymera Therapeutics by 3.6% during the 1st quarter. Comerica Bank now owns 21,374 shares of the company’s stock valued at $585,000 after acquiring an additional 743 shares in the last quarter. Finally, Hsbc Holdings PLC boosted its position in Kymera Therapeutics by 6.1% during the 1st quarter. Hsbc Holdings PLC now owns 18,547 shares of the company’s stock valued at $508,000 after acquiring an additional 1,064 shares in the last quarter.

Insider Buying and Selling at Kymera Therapeutics

In related news, Director Jeffrey W. Albers sold 6,349 shares of Kymera Therapeutics stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $49.00, for a total transaction of $311,101.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $49.00, for a total value of $1,470,000.00. Following the sale, the chief executive officer now directly owns 660,482 shares of the company’s stock, valued at $32,363,618. This represents a 4.34% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 48,349 shares of company stock valued at $2,334,301. Company insiders own 16.01% of the company’s stock.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.